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Fatigue absorbed her whole body, both physically and 

emotionally. There was pain in her legs below her knees, 
and they felt as though they were "filled with cement. Her 
feet were always inflamed and aching. Her fingers were 
tender and a colorful red or blue. She was losing her hair by 
the handfuls. There were nodules on her elbows and fingers 
(Aladjem 145). She had problems with her eyes, and her 
"throat hurt all the time" (Aladjem 146). These numerous 
problems were consuming the life of Henrietta Aladjem, yet 
no doctor knew what, if anything, was wrong with her. 
They simply led her to believe that it was all in her head. 
Henrietta Aladjem was finally diagnosed with lupus after 
several months. By this time her kidneys were severely 
damaged. Furthermore, there was no known cure for lUpus. 
In 1958, her lupus went into remission and stayed in 
remission for more than thirty-two years. No one knew why 
she went into remission, or why it has lasted so long. She 
has not forgotten her battle with this vicious disease, 
however. Aladjem has written books about lupus and works 
with the Lupus Foundation of America in hopes of teaching 

others about this mysterious disease (Aladjem 153). 
As one can tell from Aladjem's description, lupus is a 
devastating disease. Even its name, which means wolf in 
Latin, suggests the fierceness of this disease. Lupus, which 
is short for systemic lupus erythematosus (SLE)' is not rare 
(Hales 60). "It is more prevalent than muscular dystrophy, 
multiple sclerosis, cystic fibrosis, rheumatic fever, pernicious 
anemia, Hodgkin's disease, or leukemia," yet it is virtually 
unknown to the general population (Aladjem 8). Lupus has 
been diagnosed in approximately 500,000 Americans. 
Ninety percent of those diagnosed with lupus are women. It 
has been estimated that lupus affects half a million more 
people, but they do not know what is wrong (Hales 60). In 
addition, SLE affects black women three times more often 
than white women (Aladjem 4). Most of the women are in 
their childbearing years with an average age of twenty-nine 
(Blau and Schultz 31). 
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Most lupus patients have only mild, or possibly 

moderate, symptoms of this disease. Yet, 10% have the 
life-changing, and potentially life-threatening, SLE that 
Henrietta Aladjem described (Hales 60). One might ask, 
what exactly is lupus? And, what would be capable of 
causing a disease to be so variable in each individual it 
strikes? Obviously, SLE is a multisystem disease that can 
affect everything from the skin to the heart and lungs 
(McCarty, Valencia, and Fritzler 8). It is also a collagen­
vascular disease, which implies the involvement of 
connective tissue and blood vessels (Aladjem 9). In addition, 
it is an inflammatory autoimmune disorder, which means that 
the body attacks its own tissues (Hales 60). Although 
researchers have classified lupus in several ways, they have 
not been able to find the exact cause of this disease. 
SYMPTOMS 
Perhaps the best way to understand the complexity of 
lupus is to look at how it manifests itself in the body. 
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Essentially, what symptoms might a twenty-five year 

old black female show if she has systemic lupus 
erythematosus? "SLE can affect any part of the body" 
(Aladjem xvi). However, most patients experience only a 
few of the many symptoms associated with SLE. Some of 
the patient's symptoms may be rashes, joint pain, fever, 
weight loss, fatigue, anemia, heart problems, kidney and 
sensory malfunction, false-positive tests for syphilis, 
sensitivity to the sun, pleurisy and pneumonia, hair loss, 
mental or emotional problems, nausea, vomiting, and 
jaundice (Blau and Schultz 1 0). Other symptoms include 
Raynaud's phenomenon (the toes or fingers turn blue or 
white), mouth ulcers, muscle pain, lung problems, and liver 
enlargement (Aladjem xvii-xviii). Again, one must remember 
that each SLE patient is different and that the disease will 
affect that person in its own way. It has been noted, 
however, that some symptoms are commonly recognized 
before others. The first symptoms usually include "mild, but 
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persistent aching in the joints," rashes, a low, persistent 

fever, fatigue, weight loss, loss of appetite, swollen lymph 
nodes, and sensitivity to the sun (Blau and Schultz 11-12). 
In addition to knowing the symptoms of SLE, researchers 
also know the frequency with which they occur in SLE 
patients. The symptoms and their frequencies are as 
follows: 
Arthralgia (achy joints) 95% 
Fever over 100°F (3SOC) 90% 
Arthritis (swollen joints) 90% 
Skin rashes 74% 
Anemia 71% 
Kidney involvement 50% 
Pleurisy 45% 
Butterfly rash 42% 
Photosensitivity 30% 
Hair loss 27% 
Raynaud's phenomenon 17% 
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Seizures 15% 
Mouth ulcers 12% 
(Aladjem xvi). 
CRITERIA FOR SLE 
Because of the many symptoms listed above, systemic 
lupus erythematosus is a very difficult disease to diagnose. 
It often manifests itself in so many ways that one case of 
SLE appears virtually unrelated to another case. In 1970, the 
American Rheumatism Association developed its first set of 
criteria for SLE. There were fourteen categories with a total 
of twenty-one manifestations. In order to be diagnosed with 
SLE, patients had to exhibit at least four of the fourteen 
items. The problem with this standard was that only 67% of 
one doctor's SLE patients actually had four manifestations at 
the time a diagnosis was needed, but 94% of the patients 
eventually met the criteria over a period of time (Wallace and 
Dubois 17). This lack of ability to diagnose patients at the 
time they were having a few symptoms, along with other 
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problems with the 1970 criteria, led to the development of a 

revised list of criteria that was published in 1982. The 
criteria are as follows: 
(1) 	 Malar, or butterfly, rash. This rash is located on 
the nose and cheeks. It may be flat or raised. 
(2) 	 Discoid rash. This is expressed as "reddish 
raised patches" on the body. The patches are 
"disc-shaped, thick, and scaly" (Blau 18). 
(3) 	 Photosensitivity. An unusual reaction to the sun 
results in a skin rash. 
(4) 	 Oral ulcers. These are ulcers in the throat or 
mouth that are usually painless. 
(5) 	 Arthritis. This involves more than one peripheral 
joint, including those of the lower jaw, shoulders, 
arms, hands, hips, feet, and legs. The arthritisis 
characterized by tenderness, swelling, and pain 
upon use of the joint. 
(6) 	 Serositis. 
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(a) Pleuritis. The pleura, which is "the 

membrane lining of the chest," is inflamed 
(Blau and Schultz 19). Or, 
(b) 	 Pericarditis. The pericardium, which is "the 
outer membrane surrounding the heart," is 
inflamed (Blau and Schultz 1 9). 
(7) 	 Renal disorder. 
(a) 	 Proteinuria. The levels of certain proteins 
in the urine are increased . Or, 
(b) 	 Cellular Casts. These cellular casts are 
"fragments of elements normally found in the 
blood" (Blau and Schultz 19). The elements 
may be "red cell, hemoglobin, granular, 
tubular, or mixed" (Wallace and Dubois 18; 
McCarty, Valencia, and Fritzler 8). They 
suggest the presence of blood in the kidney. 
(8) 	 Neurologic disorder. 
(a) 	 Seizures. Or, 
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(b) Psychosis. 

(9) 	 Hematologic disorder. This is a result of a 
shortage of different types of blood cells. 
(a) 	 Hemolytic anemia. This results from "too 
rapid destruction of red blood cells" (Blau 
and Schultz 19). Or, 
(b) 	 Leukopenia. This is a lack of platelets. 
Or, 
(c) 	 Lymphopenia. This results from a lack of 
white blood cells. Or, 
(d) 	 Thrombocytopenia. This is a deficit in 
thrombocytes. 
(1 0) 	 Immunologic disorder. 
(a) 	 Positive LE cell test. This is the lupus 
erythematosus cell test. When it is 
positive, "white blood cells that have 
ingested nuclei from damaged cells" are 
present (Aladjem xxi). Or, 
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(b) 	 Anti-DNA. The antibody to native DNA is 
present in an abnormal titer. Or, 
(c) 	 Anti-Sm. The antibody to the Smith antigen 
is present. Or, 
(d) 	 False-positive syphilis test. 
(11) 	 Antinuclear antibodies. These antibodies can 
be detected by an assay such as 
immunofluorescence. 
As with the 1970 criteria, a person is considered to 
have systemic lupus erythematosus if they meet four of the 
eleven criteria at the same time or during different times of 
observation. The above list of criteria have been compiled 
from Aladjem (xx-xxi); Blau and Schultz (18-19) ; McCarty, 
Valencia, and Fritzler (8-9); Schur (6-7); and Wallace and 
Dubois (18). 
THE IMMUNE SYSTEM 
Systemic lupus erythematosus "is an example of the 
immune system gone awry" (Aladjem 21). The immune 
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system is the body's defense against foreign invaders. The 
goal of this system is to distinguish between its own 
substances and foreign substances (Stryer 889). The 
immune response to nonself antigens involves one of two 
different strategies. One strategy is the humoral immune 
response. In this response, antibodies against the foreign 
antigen are synthesized by B lymphocytes. The antibodies 
bind the antigens, and the complex is either precipitated or 
identified for destruction by macrophages (Mathews and van 
Holde 248). The other strategy, the cellular immune 
response, involves T lymphocytes, which kill foreign cells. 
The T lymphocytes are also involved in the humoral response 
because they assist the B lymphocytes in functioning (Stryer 
889). By looking at the two normal immune responses and 
their components in detail, one can better understand the 
immune system, and thus, the effects of lupus on it. 
Lymphocytes 
The humoral immune response centers on the proper 
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functioning of lymphocytes, a specialized group of white 

blood cells (Blau and Schultz 62). Using monoclonal 
antibodies, lymphocytes have been divided into two groups: 
antigen specific cells and antigen nonspecific cells. T cells 
and B cells, which make up 85 % of the total blood 
lymphocytes, fall into the antigen specific category (Wallace 
and Dubois 195). 
The T cells have a receptor that is made of "a two chain 
heterodimer with an antigen binding variable region 
homologous to the B cell imm,unoglobulin receptor" (Wallace 
and Dubois 195). The antigen that is associated with the 
antigen binding region is called the T3 surface antigen and is 
found on all mature T cells. The T3 + cells are classified 
according to which monoclonal antibody they react with. 
Those that react with T4 monoclonal antibodies are 
inducer/helper cells, and the ones that react with T8 
monoclonal antibodies are cytotoxic/suppressor cells. Using 
other monoclonal antibodies, the T 4 + lymphocytes can be 
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further classified as suppressor inducer cells or helper cells 

(Wallace and Dubois 195). 
As with most classification systems, however, there are 
exceptions to the rules. Even though the T 4 + cells are 
classi"fied as inducer/helper cells, there are certain T 4 + cells 
that recognize and kill cells which have "foreign Class II (DR) 
markers," and other T 4 + cells that possess suppressive 
abilities. Some T8 + cells are exceptions to the rules, also. 
Recall that T cells fall into the antigen specific category. 
Typically, T8 + cells'stain very brightly when they react with 
the T8 monoclonal antibody. These are classified as antigen 
specific cells because they recognize and react with "Class I 
histocompatibility determinants." Some T8 + cells, however, 
stain dimly and represent a separate population that is not 
activated by the class I markers. These dim T8 + cells are 
classified as antigen nonspecific cells because they can be 
stimulated by Iymphokines directly (Wallace and Dubois 
195). 
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Like the majority of T cells, B lymphocytes are classified 

as antigen specific. These cells are believed to be derived 
"from the bone marrow (Sheeler and Bianchi 648). B 
lymphocytes display two classes of immunoglobulin 
receptors: IgM and IgD. They have other specific surface 
markers that can be detected by monoclonal antibodies B 1 
and Leu 12 (Wallace and Dubois 195). 
Lymphocytes that do not have B cell markers or react 
with T3 antigen are antigen nonspecific cells. They are also 
known as null cells. Throughout the 1970's, it was thought 
that null cells did not have the CD2 receptor, also known as 
the receptor for sheep erythrocytes. Now, it is known that 
monoclonal antibodies which detect the CD2 receptor react 
with the null cells. This is important because the presence of 
the CD2 receptor was once a speci"fication for the T cells. 
Another type of receptor, the CR3 receptor, is found on all 
null cells. This receptor reacts with the iC3b complement 
component (Wallace and Dubois 1 95-1 96). 
15 
There are two principal groups of null cells: L cells and 

other. The L cells "display high density Fc receptors for IgG, 
mediate natural killer and antibody-dependent cytotoxic 
activity, and suppress antibody production." The "other" null 
cells do not have the Fc receptors, but do have the CR3 
receptors. They suppress the production of antibodies and 
amplify the proliferation of antibodies (Wallace and Dubois 
196). 
To be able to fully comprehend the complexity of the 
overall immune response, one must understand that every 
lymphocyte cannot function completely on its own. For 
instance, the T4+ inducer/helper cells cannot recognize 
foreign antigens by themselves. In order for these 
lymphocytes to recognize an antigen, the antigen must be in 
combination with self HLA DR, which are the gene products 
of the Class II major histocompatibility complex (MHC). The 
intensity and quality of the immune response is determined 
by the self DR molecules. The primary function of the HLA 
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DR is to stimulate helper cells that promote production of 
antibodies, or to stimulate suppressor cells that produce a 
state of tolerance or nonresponsiveness. These lymphocyte 
responses are "MHC-restricted immune responses" because 
they require self-recognition (Wallace and Dubois 197). 
T8 + lymphocytes, like the T4 + cells, are self-reactive. 
These T8 + cells can be sensitized to a virus. In order for the 
sensitized lymphocytes to then kill the virally infected cell, 
the viral antigen must be in combination with "self Class I 
MHC gene products." In other words, both the antigen and 
the MHC markers must be together to be recognized by the 
T8 + cells (Wallace and Dubois 197). 
Humoral Immune Response 
In the past, it was believed that B cells that had the 
potential to make autoantibodies were removed from the 
immune system at birth. Now, it is known that B cells 
capable of making autoantibodies such as anti-DNA are 
present in the blood of healthy individuals (Wallace and 
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Dubois 197). B cells, however, are not activated solely by 

antigen. The antigen must be in combination with T helper 
cells in order to activate B cells (Aladjem 22). Therefore, 
autoantibodies are usually not present in the blood because 
of the lack of T cell help or because of active suppression 
(Wallace and Dubois 198). 
These B cells and T cells are central to the humoral 
immune response to foreign antigens. The humoral immune 
response occurs according to the clonal selection theory, 
which explained many of the problems in conceptualizing the 
immune response when it was developed. Some of the ideas 
that were explained are as follows. Production of antibodies 
rises exponentially when an antigen is present because of a 
tremendous increase in the amount of antibody-producing 
cells. Secondly, when an antigen appears for the second 
time, the response is much greater and much stronger 
because more cells against that antigen are already present. 
In addition, the "deletion of an entire clone of cells" results 
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in immunological tolerance to that particular antigen (Ada and 

Nossal 66). The immune response, according to the clonal 
selection theory, can be divided into 3 steps: (1) Antigen 
presentc;ltion, (2) T-cell activation, and (3) B-cell maturation 
(Wallace and Dubois 197). 
In the first step, the antigen is recognized by T inducer 
cells. Recall that in order for the T inducer cell to be 
activated, the antigen must be in combination with self DR 
molecules, which are presented by a macrophage. Upon 
interaction of these cell types, two growth factors are 
secreted. One growth factor is interleukin 1 (lL-1), which is 
secreted by the macrophage and influences both T-cell and 
B-cell differentiation. The other growth factor, secreted by T 
cells, is interleukin 2 (lL-2). It is responsible for"activation 
and clonal expansion of T cells" (Wallace and Dubois 198). 
The second step "is the activation and proliferation of 
other resting T cells responsive to antigen." Because resting 
T helper cells do not have receptors for interleukin 2, they 
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cannot bind that particular Iymphokine. After antigen­
presenting cells activate the T helper cells, IL-2 receptors 
develop. The T helper cells are then able to undergo clonal 
expansion and secrete B cell helper factors, known as "T-cell 
replacing factors" (Wallace and Dubois 198). 
In the final step, B cells are activated and matured to 
antibody-secreting cells (Wallace and Dubois 198). B 
lymphocytes are derived from B stem cells that are located in 
the bone marrow. Each B lymphocyte produces an 
immunoglobulin molecule that has a binding site capable of 
recognizing specific shapes. These immunoglobulins, or 
antibodies, are located on the outer surface of the B 
lymphocyte. When an antigen binds to one of these 
antibodies, the B lymphocyte is stimulated to replicate and 
produce plasma cell clones (Mathews and van Holde 250). 
This process is aided by the previously mentioned T-cell 
replacing factors that are derived from the T helper cells. 
The first T-cell replacing factor is B-cell growth factor 
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(BCGF), which is a Iymphokine that combines with antigen to 
induce B-cell proliferation. The second T-cell replacing factor 
is B-cell differentiation factor (BCDF). It is a Iymphokine that 
"stimulates activated B cells to synthesize antibody." 
Neither of these Iymphokines are MHC-restricted; thus, they 
can act on any B cell. The most important thing to 
remember is that binding of a ligand to the B cell antigen 
receptors and the presence of T-cell replacing factors are 
necessary for a B cell to become immunoglobulin-secreting 
cells (Wallace and Dubois 198). 
Once the third step is completed, the antibodies that 
were secreted by the plasma cells can rid the body of the 
foreign antigens in several different ways. First, the 
immunoglobulins may interact with soluble, or free, antigens 
and cause precipitation of the antigen-antibody complex. 
Secondly, the antibodies and the surface antigens of the 
foreign particle may interact and cause agglutination. 
Macrophages then rid the body of these complexes by 
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phagocytosis. Finally, the antibodies may promote 
complement fixation, which involves a cascade of reactions 
following the binding of complement proteins to antigen­
antibody complexes (Sheeler and Bianchi 657-659). 
Cellular Immune Response 
Both the humoral and the cellular immune responses are 
involved in the defense of the body, but they have different 
functions. The role of the humoral immune response is to 
"combat bacteria and viruses in extracellular media." The 
cellular immune response, however, "destroys virus-infected 
cells, parasites, and cancer cells" (Stryer 911). 
In addition to having a different function than the 
humoral immune response, the cellular immune response also 
has a very different mechanism for killing the foreign 
invaders. Cytotoxic, or killer, T cells play the central role in 
the cellular immune response. Unlike the soluble antibodies 
of the humoral response, the T cells carry their own receptor 
molecules on their surface. T cells, like antibodies, have 
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many different binding specificities (Mathews and van Holde 

254). However, unlike antibodies, they only recognize short 
peptides sequences (less than 10 residues). "In essence, 
antibodies recognize native macromolecules, whereas T cell 
receptors recognize fragments derived from them" (Stryer 
912). These fragments must be bound to proteins of the 
major histocompatibility complex in order to be recognized by 
the T cell receptor. Once an appropriate antigen-MHC 
protein complex is identified by a killer T cell, the T cell 
releases perforin. Perforin is a protein that causes the 
formation of pores in the foreign cell's plasma membrane. 
Basically, these pores kill the cell by allowing the critical 
components of the cell to diffuse out (Mathews and van 
Holde 254). 
An example of the cellular immune response can be 
seen in the way that the body responds to viral infection. 
When a virus attacks a cell, the virus breaks down into two 
components--the nucleic acid, which enters the host cell, and 
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the proteins in the viral coat, which stay at the surface of the 

cell. Because the infected cell now has both viral antigens 
and Class I MHC markers, it can be recognized by the 
cytotoxic T cells. The cytotoxic T cells then attach 
themselves to the infected cell and kill it before the virus has 
a chance to replicate. This is done by the transfer of 
cytotoxins into the infected cell. One cytotoxic T cell is 
capable of killing several host cells (Sheeler and Bianchi 662). 
ABNORMAL IMMUNE RESPONSE IN SlE 
As previously described, the immune system normally 
works together in a very precise manner to protect the body 
from foreign antigens that can cause infection, inflammation, 
and other problems. In systemic lupus erythematosus, 
however, this delicate balance is upset, and the body no 
longer functions in its orderly way. Through looking at the 
various effects of SLE on the immune system, one can better 
understand the disease itself and the necessity of a properly 
working immune system. 
24 
Abnormal Lymphocyte Amounts 

Lymphocytes play the central role in both the humoral 
and the cellular immune responses. Therefore, changes in 
the overall numbers and/or in the percentages of the 
lymphocytes should have noticeable effects on the immune 
response. This is precisely what appears to happen. Overall, 
T cell, B cell, and null cell numbers are usually decreased in 
patients with active SLE. All subsets of the lymphocytes 
have decreased absolute counts because of lymphopenia. 
The relative percentages of each subset, however, may be 
decreased, normal, or increased. The total percentage of T 
cells is usually normal. T3 + lymphocyte percentages are 
often decreased, especially in patients receiving prednisone 
for treatment. T8 + lymphocytes (cytotoxic/suppressor cells) 
have normal or increased percentages, while T4 + 
lymphocytes (inducer/helper cells) have decreased 
percentages. This results in a T 4 + to T8 + ratio that is 
abnormally low. The percentage of B cells in SLE is normal 
25 

or decreased. The percentage of antigen nonspecific 

lymphocytes (null cells) is decreased. In addition, the 
proportions of the two major subsets of null cells (L cells and 
other) are reversed. The percentage of L cells is greatly 
decreased (Wallace and Dubois 200), while the "other" 
category is increased (Wallace and Dubois 1 96). There is 
evidence that "a strong relationship exists between high 
titers of antilymphocyte antibodies, disease activity, and the 
lymphopenia of SLE" (Wallace and Dubois 200). 
Abnormal B Lymphocyte Function 
Many researchers have found that the B cells of SLE 
patients are hyperactive (Aladjem 28). Wallace and Dubois 
discuss the presence of B cell hyperactivity and the specific 
functions of the B lymphocytes that are increased (200). 
These hyperactive functions are as follows: reactions 
between antibodies and certain viral antigens, 
immunoglobulin turnover rates, and blood mononuclear cells 
that proliferate spontaneously (thousandfold increase). In 
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addition, "lymphocytes in B cell-enriched fractions" 
proliferate spontaneously in patients that have active SLE 
and in those with inactive SLE (Wallace and Dubois 200). 
B cell hyperactivity is not an isolated occurrence, 
however. It is observed along with T cell activation. There 
is a known correlation between immunoglobulin-secreting 
cells and "endogenously activated T cells." SLE patients 
show an increase in the number of activated B cells and an 
increase in the number of B cell precursors in the bone 
marrow and in the peripheral blood, as well as the increase in 
activated T cells (Wallace and Dubois 201). 
Although there is an increase in spontaneous activity, B 
cells secrete immunoglobulin in unusually low amounts in 
response to the pokeweed mitogen (PWM). This occurs in 
both active and inactive SLE. Different theories about the 
lack of reactivity to pokeweed mitogen exist. Because PWM 
is T cell dependent, one possible theory is that increased 
suppression or decreased helper activity by lymphocytes 
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could cause the lowered reactivity. Another possible theory 
deals with the activation of B cells. In patients with active 
SLE, B cells may be spontaneously activated. Once the B 
cells are activated, they should not be expected to respond 
to pokeweed mitogen. However, patients with inactive SLE 
may have an impaired response to pokeweed mitogen also. 
Because they have low levels of spontaneous B cell 
activation, this above explanation is invalid (Wallace and 
Dubois 201). 
The lack of B cell response to pokeweed mitogen can be 
corrected by providing B cell growth factors or helper cells. 
By adding autologous T 4 + lymphocytes, immunoglobulin 
production by SLE B cells can be increased to normal. 
Therefore, it appears that "the decreased percentages of 
T4 + inducer/helper cells along with proportionately 
increased suppressor lymphocyte subsets ... contribute to 
defective B cell responsiveness in SLE." In addition to the 
pokeweed mitogen studies, the production of antigen specific 
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antibodies has been studied. The results confirm that SLE B 

cells are hyporesponsive and that the hypo responsiveness is 
caused by a T helper cell defect (Wallace and Dubois 201). 
Abnormal T Lymphocyte Function 
The abnormal behavior of T lymphocytes described 
above interferes with their ability to interact with other cells. 
It has been shown that when normal T lymphocytes are 
combined with SLE serum, normal T suppressor cells cannot 
develop (Aladjem 28). Furthermore, the proliferation of 
disease lymphocytes and normal lymphocytes is inhibited. 
The IgG fractions in these sera were inhibited as well. 
Studies have also shown that the proliferation of 
lymphocytes upon contact with soluble antigens is decreased 
in SLE. Additionally, the responsiveness of T lymphocytes to 
allogenic lymphocytes and in the "autologous mixed 
lymphocyte culture (AMLR)" is decreased. Normally, in the 
AMLR, major histocompatibility complex markers on non-T 
cells are recognized by T 4 + lymphocytes. Interleukin 2 is 
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secreted, and T4 + and T8 + cells proliferate. However, 
because SLE T 4 + cells cannot produce interleukin 2, the 
AMLR is decreased in SLE (Wallace and Dubois 202). 
In essence, the decrease in SLE lymphocyte proliferation 
is caused by one or more of three factors. The proportion of 
cultured lymphocytes may be relatively decreased; 
suppressor monocytes may be present; or factors capable of 
inhibiting proliferation may exist (Wallace and Dubois 203). 
Furthermore, decreased interleukin 1 and interleukin 2 
production contributes to the decrease in lymphocyte 
proliferation (Aladjem 28). By adding normal helper cells, 
interleukin 1, or interleukin 2, these T cell defects can be 
corrected in SLE patients (Wallace and Dubois 203). 
In addition to the defects in T lymphocyte proliferation, 
there are defects in the T helper cell activity. Activity 
induced by mitogenic lectins is decreased or normal. 
Immunoglobulin synthesis induced by pokeweed mitogen 
shows both decreased and normal helper activity. Helper 
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activity induced by specific antigens is decreased. In one 
study, SLE B cells were cocultured with normal T cells. The 
SLE B cells responded to the normal T cells. Conversely, 
however, the T cells of SLE patients were unable to help 
normal B cells. B cell colony formation, which is supported 
by the T cells, is defective in SLE patients also (Wallace and 
Dubois 205). Therefore, it can be concluded that T helper 
cell activity in SLE is abnormal regardless of the effect of the 
disease on the B lymphocytes. 
The T suppressor cell activity of T8 + cells is also 
defective in SLE patients. Normally, T cell proliferation, 
antibody production by B cells, and the generation of 
cytotoxic effector cells can be suppressed by lymphocytes 
activated by concanavalin A. In SLE, this suppressor activity 
is decreased. It has been reported that SLE patients do not 
have a particular population of short-lived lymphocytes that 
are known to circulate in the blood and to have the ability to 
suppress the lymphocyte proliferation. In addition to this 
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lack of suppressive lymphocytes, there is evidence for the 
inadequate activation of suppressor cells. This evidence 
includes a decrease in T4 + cells (inducer/helper cells), a 
decrease in interleukin 2 production, and "antilymphocyte 
antibodies cytolytic for T 4 + suppressor inducer cells as well 
as T8 + suppressor effector cells." Reports have shown that 
proper suppressor signals can overcome this regulatory 
defect. Therefore, decreased suppressor activity can result 
not only from a lack of suppressor cells but also from 
inadequate induction. Furthermore, inadequate suppression 
can be caused by the increased number of T8 + lymphocytes 
that inhibit interleukin 2 production (Wallace and Dubois 
206). 
In addition to the numerous other problems with T 
lymphocytes, SLE patients have decreased "antibody­
dependent cellular cytotoxicity (ADCC)" that correlates with 
disease activity. In other words, certain lymphocytes that 
have Fc receptors for IgG possess the ability to kill cells 
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coated with IgG. The sera of SLE patients contain IgG 

lymphocyte antibodies or immune complexes that can block 
ADCC. However, these IgG antibodies are also capable of 
inducing ADCC against T lymphocytes. In studies, "normal T 
cells sensitized with SLE serum became target cells in 
ADCC." This may help to explain the lymphopenia of SLE 
(Wallace and Dubois 206). 
Abnormal Natural Killer Cells 
Natural killer cells, or NK cells, are responsible for 
injecting cytotoxins into virus-infected cells during the 
immune response. When the NK cell and the infected cell 
interact, interferon is produced in great amounts. It is 
responsible for the rapid proliferation of the natural killer cells 
(Sheeler and Bianchi 669). Like the B cells and the T cells of 
an SLE patient, the natural killer cells act abnormally. Their 
activity is decreased (Aladjem 30). It has not yet been 
established whether or not this decrease in activity correlates 
with the presence of active disease. A few possible 
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explanations for the natural killer cell defect exist. The NK 

cell may have an intrinsic defect; there may be inhibition of 
NK cell activity by corticosteroid treatment; or the SLE serum 
may contain antilymphocyte antibodies. The last possibility 
seems to be the most probable because "antilymphocyte 
antibodies specific for NK cells have been described" 
(Wallace and Dubois 206). 
Two Iymphokines, interferon and interleukin 2, play 
important roles in NK cell activity. In normal controls, 
interferon and interleukin 2 greatly enhance NK cell activity. 
Interleukin 2 can stimulate Leu 11 + cells to secrete gamma 
interferon. The effect of interferon on natural killer cell 
activity in SLE patients has been variable in studies. 
Interferon did not enhance low NK cell activity in SLE 
patients, but it did augment the activity of patients that 
already had high natural killer cell activity. In another study, 
interferon only had a modest effect on NK cell activity, while 
interleukin 2 augmented the cytotoxicity of natural killer cells 
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to normal levels (Wallace and Dubois 206). 

Overall, it appears that natural killer cell activity in SLE 
patients is abnormal because of a significant decrease in the 
number of NK cells, the presence of antilymphocyte 
antibodies capable of blocking cytotoxicity, and a decreased 
response to Iymphokines (Wallace and Dubois 207). 
Abnormal Monocytes 
Normally, monocytes have a regulatory role in various 
aspects of the immune response. They help regulate the 
proliferation of lymphocytes, the production of Iymphokines, 
and the activation and maturation of T cells and B cells. SLE 
monocytes, however, behaved abnormally in several 
experiments. They inhibited pokeweed mitogen-induced 
immunoglobulin production. When the monocytes were 
removed, immunoglobulin production increased. Monocytes 
blocked the B cell response to "Staphylococcus aureus 
Cowan I antigen," also. This can be explained as follows. 
Immunoglobulin synthesis by B cells can be enhanced by 
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interleukin 1. Although the monocytes are capable of 

producing IL-1, the production of IL-1 inhibitors can be 
stimulated by immune complexes, which are often present in 
the blood of SLE patients. In addition, decreased interleukin 
1 production has been reported in SLE. Studies have shown 
that the addition of interleukin 1 and interleukin 2 allows 
lymphocyte function to overcome the suppressive effects of 
abnormal SLE monocytes (Wallace and Dubois 207). 
Normal and Abnormal Lymphokines 
Lymphokines, or interleukins, are secreted by certain T 
helper cells and are responsible for activating macrophages 
and other lymphocytes. The goal of Iymphokine secretion is 
to accumulate macrophages and lymphocytes in an infected 
region (Sheeler and Bianchi 662-663). The secretion of 
interleukin 1 and interleukin 2 is seen in the first step of the 
humoral immune response. Interleukin 1 influences T cell 
and B cell differentiation, whereas interleukin 2 helps to 
maintain "clonal growth of activated T cells" (Theofilopoulus, 
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Prudhomme, and Dixon 203). 
In SLE, the production of both interleukin 1 and 
interleukin 2 is decreased. It is possible that IL-1 inhibitory 
factors decrease interleukin 1 activity. Recall that IL-1 
inhibitors can be produced by monocytes, which can be 
stimulated by immune complexes. There is also a decrease 
in the production of interleukin 2 by SLE lymphocytes. This 
was found in patients with active SLE, as well as in patients 
with inactive SLE, thus making this defect different from 
other SLE T cell defects (Wallace and Dubois 204). Although 
IL-2 inhibitors are present in the serum, their levels seem to 
be decreased. Another possible cause of decreased 
interleukin 2 production could be a problem with T 4 + 
lymphocytes (Theofilopoulus, Prudhomme, and Dixon 204). 
However, the decreased interleukin 2 production exists in 
SLE patients with and without normal percentages of T 4 + 
lymphocytes. Furthermore, it has been found that the T 4 + 
lymphocytes' capacity to produce interleukin 2 is intact. The 
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actual cause of decreased IL-2 production seems to be the 

"spontaneously activated T8 + lymphocytes. n When T8 + 
lymphocytes are removed, IL-2 production in active and in 
inactive SLE is restored. The readdition of T8 + cells inhibits 
production of interleukin 2 again. Thus, it is believed that 
interleukin 2 production is inhibited by T8 + lymphocytes 
(Wallace and Dubois 204). 
In the immune response, interleukin 2 stimulates the 
production of interferon, which is another type of Iymphokine 
(Blau and Schultz 69). Because interleukin 2 is very 
important in the humoral immune response, the effects of 
interferon on antibody production are important also (Wallace 
and Dubois 204). As mentioned earlier, interferon is also 
necessary for the proliferation of natural killer cells (Sheeler 
and Bianchi 669). In SLE patients, the levels of interferon 
are elevated even though interleukin 2 levels are decreased. 
This seeming paradox has not yet been explained (Blau and 
Schultz 69). 
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It is known that there are three classes of interferon: 

alpha, beta, and gamma. Alpha interferon is acid stable and 
is capable of increasing natural killer cell activity and 
activating nonspecific suppressor cells. Gamma interferon is 
acid labile and is able to inhibit proliferation of lymphocytes 
and enhance maturation of B cells. SLE patients, however, 
have increased levels of an "acid labile alpha interferon." No 
one knows the biological effects of this unusual interferon 
(Wallace and Dubois 204). 
B Cell Hyperactivity 
All of the factors described above contribute to the 
abnormal immune response, which seems to be characterized 
by the hyperactivity of B cells. B cell hyperactivity is most 
likely caused by several mechanisms that work together and 
produce excess antibodies. In murine SLE-like diseases, a 
primary B cell defect exists at the level of the stem cell. In 
addition, hypergammaglobulinemia and autoantibodies 
provide evidence for an inherited primary B cell defect 
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because they are found in SLE patients, as well as in family 

members and identical twins who are not afflicted by the 
disease (Wallace and Dubois 208). 
SLE B cells do not act alone, rather they are regulated 
by other cells. Recall that in SLE, B-cell growth factor levels 
are increased, and that they "may be produced by T helper 
cells or certain CR3 + non-T cell subsets." Lymphokines can 
stimulate the CR3 + lymphocytes without an antigen 
present. Because of this possibility, the increased amounts 
of alpha interferon could stimulate SLE B cells to produce 
immunoglobulin or to maintain production of B-cell growth 
factors. In addition to this, it is known that soluble factors 
that increase B cell activity can be secreted by the B cells 
themselves (Wallace and Dubois 208). 
Another aspect of B cell activity to be considered is the 
relationship between B cell hyperactivity and decreased 
interleukin 1 and interleukin 2 production. Recall that 
production of interleukin 2 is decreased in patients with 
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active and inactive SLE. Because of this, it is likely that the 
decrease in interleukin 2 production is a "primary defect that 
may be related to impaired generation of suppressor cell 
function." It is possible that the lymphocytes that produce B 
cell growth factor require less IL-2 than what is needed for 
the activation of suppressor cells. If this is true, "then 
correction of the IL-2 defect might result in the activation of 
suppressor cells capable of inhibiting the production of B cell 
growth factors" (Wallace and Dubois 208). 
The suppressor cell defect, however, could only be 
corrected if the appropriate subsets are present for 
suppressor cell activation. Antilymphocyte antibodies that 
are present in SLE can deplete the T 4 + suppressor inducer 
cells, and inadequate suppression would result even with 
normal levels of interleukin 2. Because patients with inactive 
SLE almost always have normal amounts of T-cell subsets 
and low levels of antilymphocyte antibodies, B cell 
hyperactivity cannot always be attributed to decreased 
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numbers of suppressor inducer cells (Wallace and Dubois 

209). 
It seems that researchers have a great deal of 
information about the abnormalities of the SLE immune 
response. They know that the numbers of lymphocytes are 
decreased, some of the ways that Band T lymphocytes are 
abnormal, the problems with the natural killer cells and 
monocytes, and the abnormal functions of the Iymphokines. 
They are also quite sure that, in some way, all of these 
problems contribute to B cell hyperactivity, which seems to 
playa great role in SLE. Despite all of this knowledge, 
however, they still cannot clarify the exact mechanisms for B 
cell hyperactivity and the abnormal immune response. This 
area, then, is under continuous research and study in hopes 
of someday discovering exactly how SLE affects the immune 
system. 
AUTOANTIBODIES IN SLE 
By looking at the normal immune response and the 
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abnormal SLE immune response, one can only begin to 

comprehend the complexity of a mUlti-system autoimmune 
disease like SLE. One manifestation of this disease is the 
presence of autoantibodies in SLE serum. The most 
significant of the autoantibodies are those that are directed 
indiscriminately against nuclear antigens, the antinuclear 
antibodies (Blau and Schultz 20). As one of the criteria for 
the American Rheumatism Association's classification of 
SLE, the presence of antinuclear antibodies (ANA) obviously 
plays a great role in the development and in the detection of 
the disease (McCarty, Valencia, and Fritzler 8). 
Immunofluorescence 
Tests for antinuclear antibodies have been positive in 
more than 90% of SLE patients, and in less than 5 % of other 
people. The only exception to these results is in patients 
with rheumatoid arthritis, two-thirds of which may have 
ANA, but at lower levels than SLE patients (Blau and Schultz 
20). Antinuclear antibodies are detected by 
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immunofluorescence. In this technique, patient samples and 

an antigen substrate are incubated together to allow the 
specific binding of cell nuclei and autoantibodies. An 
antigen-antibody complex is formed if ANA are present. 
Antibodies that are not specifically bound are washed off. 
An "anti-human antibody reagent conjugated with 
fluorescein" is then incubated with the substrate (McCarty, 
Valencia, and Fritzler 42). After being washed a second 
time, a fluorescent microscope is used to view the slides 
(Wallace and Dubois 229). When positive results are 
obtained, a stable three-part complex exists where the 
fluorescent antibody is bound to the human antinuclear 
antibody that is bound to the nuclear antigen. This complex 
will be a fluorescent apple-green. If the results are negative 
for antinuclear antibodies, there will be no fluorescence 
(McCarty, Valencia, and Fritzler 42). 
Once positive results for the immunofluorescence­
antinuclear antibody test (lFA-ANA) are obtained, the 
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resulting pattern can help determine the type of antinuclear 

antibody present. There are three types of ANA patterns 
that may indicate the presence of SLE. These patterns are 
most easily seen in cells undergoing mitosis, which greatly 
increases the ability to determine the antigen specificity of 
these autoantibodies. Before cell division, most nuclear 
antigens are uniformly distributed throughout the nucleus. 
However, the nuclear antigens are redistributed when the 
chromosomes condense and the nuclear membrane is 
fragmented. Only antigens such as DNA and histone that are 
associated with chromosomes are able to fluoresce. During 
cell division, the other nuclear antigens, such as Sm and 
RNP, are redistributed outside of the chromosome region 
(McCarty, Valencia, and Fritzler 65). 
In the homogenous pattern, the entire nucleus is 
smoothly stained. Occasionally, the nucleoli wi'li not appear 
to be stained. In metaphase, the chromosome region is 
de"finitely positive. A homogenous pattern may indicate the 
45 

presence of the following nuclear antigens: 

deoxyribonucleoprotein (DNP), double-stranded DNA, and 
histone (McCarty, Valencia, and Fritzler 66). 
In the peripheral pattern, the smooth staining is located 
basically around the outer region of the nucleus. Weaker 
staining often occurs toward the center of the nucleus. The 
chromosome region is positive. This pattern may be 
described as shaggy or membranous. The nuclear antigens 
that may be present are double-stranded DNA, single­
stranded DNA, DNP, and histone. If staining of the 
chromosome region does not occur, it is improbable that anti­
DNA, anti-histone, or anti-DNP are present (McCarty, 
Valencia, and Fritzler 66). 
In the speckled pattern, the nucleus appears to have a 
fine, or grainy, stain . Usually, the nucleolar region is not 
stained. The chromosome region does not stain, either. The 
area outside the chromosome region stains with a varying 
intensity. The following antigens may be present: Smith 
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antigen (Sm), nuclear ribonucleoprotein (nRNP), Sjogren's 
syndrome A antigen (SS-A), or scleroderma 70 antigen (Scl­
70) (McCarty, Valencia, and Fritzler 66). 
By using the technique of immunofluorescence and 
looking at the patterns it produces, autoantibodies can be 
detected in SLE serum. These autoantibodies may be 
antibodies to DNA, antibodies to deoxyribonucleoprotein, 
antibodies to histone, or antibodies to nonhistone nuclear 
antigens. 
Antibodies to DNA 
High titers of anti-DNA antibodies do not necessarily 
make the diagnosis of SLE correct, but they strongly suggest 
the presence of that autoimmune disease. Anti-DNA 
antibodies can be categorized according to which type of 
DNA they react with. They may react with sites on double­
stranded DNA, with sites on single-stranded DNA, or with 
sites on both double-stranded DNA and single-stranded DNA 
(Glass and Schur 544). 
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Anti-double-stranded DNA antibodies are uniquely 

specific to SLE (Blau and Schultz 22). They are of the IgG or 
IgM class and are targeted to the carbohydrate phosphate 
backbone of the DNA (Glass and Schur 545). The presence 
of these antibodies is greatly increased during active SLE and 
active nephritis. By measuring a patient's antibodies to 
double-stranded DNA, their pattern of disease activity can be 
followed (Wallace and Dubois 231). 
Ninety percent of SLE patients have antibodies to 
single-stranded DNA (Blau and Schultz 22). Their presence is 
not always indicative of SLE, however, because they are 
"frequently seen in other systemic rheumatic diseases 
(Wallace and Dubois 231). Like double-stranded DNA 
antibodies, anti-single-stranded DNA is present in high titer in 
patients with active nephritis (Glass and Schur 545). 
The final class of anti-DNA antibodies reacts with both 
single-stranded DNA and double-stranded DNA. Although 
they probably recognize the carbohydrate-phosphate 
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backbone of DNA, a single strand of the backbone would not 

be sufficient to make the antibodies antigenic for both single­
stranded DNA and double-stranded DNA. One possibility for 
the antigenic site is that the single-stranded DNA may form a 
helical structure by folding back on itself. An antigenic 
determinant would be created that could react to antibodies 
specific for both single-stranded DNA and double-stranded 
DNA (Wallace and Dubois 230). 
Antibodies to Deoxyribonucleoprotein 
Deoxyribonucleoprotein (DNP) is nuclear material made 
up primarily of DNA-histone complexes (McCarty, Valencia, 
and Fritzler 31). Antibodies to DNP are indirectly responsible 
for the LE cell (lupus erythematosus cell) phenomenon 
(Wallace and Dubois 232). Basically, the anti-DNP antibodies 
react and complex with nuclei from leukocytes that have 
been disrupted. Viable leukocytes then phagocytose the 
immune complexes and form the LE cell (Glass and Schur 
541 ). Approximately 70% of SLE patients have the LE cell 
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and the antibody to DNP present in their serum. Since they 
can be found in other rheumatic diseases, however, the LE 
cell and anti-DNP antibody are not speci"fic for SLE (Wallace 
and Dubois 232). 
Antibodies to Histone 
Histones are a group of basic nuclear proteins that 
contain high ratios of the amino acids arginine and lysine. 
Antibodies to histones can react with all of the histone 
classes: "H 1, H2A, H2B, H3, and H4." H2A and H2B are 
able to complex with each other. This complex, too, is 
recognized by specific autoantibodies (Wallace and Dubois 
232). 
There are differing reports on the percentages of 
idiopathic SLE patients with antibodies to histone. Wallace 
and Dubois report that up to 86% of patients with idiopathic 
SLE have antihistone antibodies (234), while McCarty, 
Valencia, and Fritzler report that only 30% do (34). Both 
report that antibodies to histone are present in 90% or more 
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of the patients with drug-induced lupus erythematosus 
(Wallace and Dubois 234; McCarty, Valencia, and Fritzler 
35). 
Histones express a homogenous immunofluorescence 
pattern (McCarty, Valencia, and Fritzler 35). It is difficult, 
however, to be certain that the pattern represents histone 
antigen because it is so similar to the anti-DNA pattern. For 
this reason, an enzyme-linked immunosorbent assay and a 
radioimmunoassay have been developed to detect the 
presence of antihistone antibodies (Wallace and Dubois 234). 
Antibodies to Nonhistone Nuclear Antigens 
The final class of antinuclear antibodies found in SLE is 
reactive with nonhistone nuclear proteins. In IFA-ANA tests, 
these nonhistone proteins express the speckled pattern. This 
pattern may be due to different antigenic specificities. 
Because it is "one of the least specific ANA patterns," the 
antigen is further detected by immunodiffusion (ID), passive 
hemagglutination (PHA), or counterimmunoelectrophoresis 
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(CIE). There are six types of nonhistone nuclear proteins that 

may be present in SLE: Smith antigen, nuclear 
ribonucleoprotein, Sjogren's syndrome A antigen and B 
antigen, MA-1 antigen, and proliferating cell nuclear antigen 
(McCarty, Valencia, and Fritzler 35). 
The antibody to the Smith antigen (anti-Sm) was the 
'first nonhistone antigen discovered (Wallace and Dubois 
235). It was described using an agarose gel precipitin 
system. The Smith antigen shows resistance to treatment 
with RNase and DNase, but is inactivated by treatment with 
periodate and trypsin. Once the immunofluorescent speckled 
pattern has been detected, the presence of Smith antigen 
can be determined by ID against calf thymus extract or rabbit 
thymus nuclear extract, by PHA, or by CIE (McCarty, 
Valencia, and Fritzler 35). If the Smith antigen is detected, 
the patient is then known to have SLE because anti-Sm 
antibody is totally specific for SLE (Blau and Schultz 22). 
Moreover, its significance is proven because it is included in 
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the antinuclear antibody criteria for SLE even though it is 

present in only 30% of SLE patients (Wallace and Dubois 
235). 
Another nonhistone nuclear antigen is nuclear 
ribonucleoprotein (nRNP). Antibodies to nRNP are present in 
highest titer in mixed connective tissue disease, which 
mimics scleroderma, SLE, and dermatomyositis. There are, 
however, high titers of antibodies to nuclear 
ribonucleoprotein in SLE (Wallace and Dubois 236). 
Obviously, unlike the anti-Sm antibody, anti-nRNP is not 
specific for SLE. However, antibody to nRNP is more 
common in SLE patients than the anti-Sm antibody is. There 
appears to be a linkage between the responses of antibodies 
to nRNP and to Smith antigen. Although the antigenic 
determinants of each are clearly independent, concurrent 
immune responses to these antigens occur much more 
frequently than is predicted by chance. Because of this, anti­
nRNP and anti-Sm are present together more often than anti­
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Sm alone (Schur 56). It has now been found that the Sm 

antigen and the nRNP antigen associate in extractable 
nuclear antigen (ENA) complexes (Wallace and Dubois 236). 
There are two types of antinuclear antibodies that occur 
primarily in patients with Sjogren's syndrome, and in a 
significant percentage of SlE patients. The two types of 
antibodies are known as anti-SS-A and anti-SS-B because 
they were first seen in patients with Sjogren's syndrome. 
When the SS-A antigen and the SS-B antigen were 
discovered, they were considered to be nuclear antigens. 
Two other antigens known as Ro and la had been discovered 
and were considered cytoplasmic antigens. It turns out that 
different researchers were describing the same antigens and 
naming them differently. Now the antibodies to these 
antigens are known as anti-SS-A/Ro and anti-SS-B/la 
antibodies. Because these antibodies are made of RNA­
protein complexes, they can be found in the nucleus and in 
the cytoplasm. RNA is made in the nucleus, but some of it 
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can be found in the cytoplasm. Therefore, the researchers 

may have been looking at the antibodies during different 
stages of the cell cycle and seeing what were thought to be 
different antigens (Wallace and Dubois 237). 
Anti-SS-AfRo antibodies can be found in 30 to 40% of 
SLE patients, and in up to 70% of Sjogren's syndrome 
patients. There are several clinical associations between 
features of SLE and the presence of anti-SS-AfRo antibodies. 
One example is the presence of "extensive photosensitive 
dermatitis" (Wallace and Dubois 238). Another example is 
the association of anti-SS-AfRo antibodies with neonatal 
lupus. Often these children have rashes and complete heart 
block (McCarty, Valencia, and Fritzler 36). In addition, the 
titers of anti-SS-AfRo change with disease activity and with 
levels of antibody to double-stranded DNA, thus making it 
possible to use this antibody to quantitate SLE activity 
(Wallace and Dubois 238). 
Anti-SS-BfLa antibodies are seen in fewer SLE patients 
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than are antibodies to SS-A/Ro. Antibody to SS-B/la is 

found in approximately 15% of SlE patients, and in 45 to 
60% of Sjogren's syndrome patients (Schur 58). There are 
no clinical manifestations of SlE directly associated with the 
presence of antibody to SS-B/la (Wallace and Dubois 238). 
Antibodies to SS-A/Ro and antibodies to SS-B/la react 
with RNA-protein complexes. The small RNAs are made up 
primarily of RNA polymerase III transcripts. It has been 
found that the SS-B/la antigen assists in "the maturation of 
RNA polymerase III transcripts." Also, the SS-B/la protein is 
known to bind EBV-associated RNA and adenovirus­
associated RNA. It is possible these viruses playa part in a 
disease where the antibody to SS-B/la is present. This is 
only a possibility , however, since little is understood about 
the soluble nuclear antigens (Wallace and Dubois 239). 
Proliferating cell nuclear antigen (PCNA) is found in 
greatest amounts in the nuclei of proliferating cells (McCarty, 
Valencia, and Fritzler 37). The antibody to PCNA does not 
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react with interphase cells that are not dividing, rather it 
reacts with rapidly proliferating cells or mitogen-stimulated 
cells. Proliferating cell nuclear antigen can be found in 
different cell types such as activated Band T lymphocytes, 
germline cells, and epithelial cells. After being stimulated by 
concanavalin A, PCNA can be seen in the nucleolus. Then it 
appears to move to the nucleoplasm and disappear in the 
"blast-transformed lymphocyte." Since PCNA is reactive 
only with dividing cells, it is immunologically distinct from 
other nuclear antigens such as DNA, Sm, nRNP, SS-A/Ro, 
and SS-B/La. In addition, it seems that PCNA is highly, or 
totally, specific for SLE (Wallace and Dubois 239). Because 
it is present in less than 10% of SLE patients, however, it is 
very hard to draw complete conclusions about this "unique 
nuclear protein " (McCarty, Valencia, and Fritzler 37-38). 
MA-1 is another nonhistone nuclear antigen. The 
antibody to MA-1 appears to be distinct in its 
immunofluorescent pattern. The beaded peripheral pattern is 
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unlike the patterns seen for other nuclear antigens such as 

nRNP, 5m, 55-A/Ro, or 55-B/La (McCarty, Valencia, and 
Fritzler 37). Using immunodiffusion in one study, twelve of 
sixty-six 5LE patients (approximately 18%) had antibodies to 
MA-1 antigen. Furthermore, in another study, this antibody 
was not seen in 554 patients with other systemic rheumatic 
diseases and normal individuals. Therefore, there appears to 
be a high specificity of anti-MA-1 antibodies for 5LE. The 
patients that have antibodies to MA-1 present represent a 
subset of 5LE because of the specific clinical manifestations 
associated with the MA-1 antigen. These features are some 
of the most severe implications of 5LE: "recalcitrant skin 
lesions, hypocomplementemia, severe renal disease, and 
neurologic abnormalities." In the study of 5LE patients with 
anti-MA-1 antibodies, the disease had taken a very 
progressive course. Three patients had MA-1 antigen 
circulating in their bodies just before the onset of nephritis. 
This association between the MA-1 antigen and nephritis 
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suggests that "MA antigen-antibody complexes may be 

present in immune-complex mediated tissue injury" (Wallace 
and Dubois 239). 
The many types of antinuclear antibodies described 
above play an important role in the diagnosis of SLE and in 
the tracking of disease activity. Because they are present in 
99% of SLE patients and are easily detected by 
immunofluorescence, antinuclear antibodies can be observed 
and recorded with ease (Wallace and Dubois 227). Then, 
using the results, the type and necessity of treatment can be 
evaluated. 
CONCLUSION 
Treating lupus is as varied as its many manifestations 
and symptoms. No specific treatment is necessary for those 
patients who are' asymptomatic except for the presence of a 
few antinuclear antibodies or LE cells. Bed rest is prescribed 
for those who are experiencing active disease. When mild 
arthritis is the main complaint, bed rest and "nonsteroidal 
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anti-inflammatory agents" are prescribed. If a patient is one 
of those 1 0% who experience a severe case of SLE with 
neurological or renal involvement, corticosteroids are 
prescribed (Wallace and Dubois 502). 
Outside of these medical recommendations and 
prescriptions, lupus patients must simply learn to live with 
the manifestations of their illness. Patients must avoid the 
sun and use protective sunscreens. They must get adequate 
rest, especially during the early stages of remission, to avoid 
triggering disease activity. SLE patients, however, must also 
get adequate amounts of exercise, especially those that 
strengthen muscles without stressing joints. Physical 
therapists can instruct patients in the proper use of exercise. 
Finally, patients should follow a well-balanced diet (Hales 
60). These recommendations hardly seem life-altering, 
however, because they should be a part of the lifestyle of a 
healthy individual, as well. 
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